title: Fanconi syndrome due to deferasirox.
abstract: Deferasirox is an innovative iron-chelating treatment. However, preliminary data have suggested that kidney toxicity may be a major issue in the management of patients receiving this drug. We report a case of Fanconi syndrome associated with acute renal insufficiency in a patient receiving deferasirox. The latter has to be added to the expanding list of drugs that may induce Fanconi syndrome. Careful monitoring of kidney function and markers of proximal tubular injury are mandatory in patients undergoing treatment with deferasirox.
authors.affiliation: Université Paris Descartes, Hôpital Necker, APHP, Paris, France.
authors.forename: Cédric
authors.initials: C
authors.lastname: Rafat
authors.forename: Fadi
authors.initials: F
authors.lastname: Fakhouri
authors.forename: Jean-Antoine
authors.initials: JA
authors.lastname: Ribeil
authors.forename: Richard
authors.initials: R
authors.lastname: Delarue
authors.forename: Moglie
authors.initials: M
authors.lastname: Le Quintrec
mesh_terms: D000368:Aged; D001565:Benzoates / Q000009:adverse effects*; D000077588:Deferasirox; D005198:Fanconi Syndrome / Q000139:chemically induced*; D006801:Humans; D007502:Iron Chelating Agents / Q000009:adverse effects*; D008297:Male; D014230:Triazoles / Q000009:adverse effects*
chemical_list: D001565:Benzoates; D007502:Iron Chelating Agents; D014230:Triazoles; D000077588:Deferasirox